Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence & Safety Data in PURPOSE 1 at the End of the Randomized Blinded Phase

Conference Reports for NATAP

Conference on Retroviruses
and Opportunistic Infections
Denver, CO 80202, United States
February 22 - 25, 2026


Twice-Yearly Subcutaneous Lenacapavir for PrEP: Updated HIV-1 Incidence & Safety Data in PURPOSE 1 at the End of the Randomized Blinded Phase

	CROI 2026 Feb 22-25 Denver